Colitis
Drug research and approvals for colitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 298 studies of colitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 161 drug trials for it since 2013, FDA has 6 approved and 17 open orphan designations naming it, and the EU has 5 authorised medicines for it.
- Recruiting worldwide: 298
- Trials authorized in Canada: 161
- FDA orphan approvals: 6
- EU medicines: 5
Recruiting now
Newest start dates first, of 298 recruiting on ClinicalTrials.gov ↗- A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With…NCT07846683 · Phase 3 · Hoffmann-La Roche · starts Nov 15, 2026
- Longitudinal Immunophenotyping of Patients With Inflammatory Bowel DiseaseNCT07619547 · Not reported · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · starts Nov 5, 2026
- Microbiome-targeted Diet Therapy in Ulcerative ColitisNCT07520461 · Not applicable · University of Minnesota · starts Nov 4, 2026
- Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal InflammationNCT07501078 · Phase 2 · Muhammad N Aslam, MD · starts Nov 1, 2026
- Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative ColitisNCT07820046 · Phase 2 / Phase 3 · Tanta University · starts Oct 25, 2026
- Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel…NCT07719426 · Not reported · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · starts Sep 17, 2026
- A Study of AC-101 Tablets in Patients With Ulcerative ColitisNCT07755241 · Phase 2 · Accro Bioscience (Suzhou) Limited · starts Sep 10, 2026
- Bacillus Probiotic Spores in Supporting the Treatment of Chronic Inflammatory Bowel DiseaseNCT07799428 · Not applicable · Anabio R&D · starts Sep 4, 2026
- A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative…NCT07747480 · Phase 1 · GlaxoSmithKline · starts Sep 3, 2026
- A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to…NCT07747467 · Phase 1 · GlaxoSmithKline · starts Sep 3, 2026
Drug pipeline
2 in phase 3, 6 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Infliximab
- Phase 3 TNF-alpha inhibitor
- Ustekinumab
- Phase 3 Interleukin-12 inhibitor
- Tacrolimus anhydrous
- Phase 2 FK506-binding protein 1A inhibitor
- Tofacitinib
- Phase 2 Janus Kinase (JAK) inhibitor
- Adalimumab
- Phase 2 TNF-alpha inhibitor
- Mesalamine
- Phase 2 Arachidonate 5-lipoxygenase inhibitor
- Mercaptopurine anhydrous
- Phase 2 Amidophosphoribosyltransferase inhibitor
- Vedolizumab
- Phase 2 Integrin alpha-4/beta-7 inhibitor
- CRS-3123
- Phase 1 Methionine--tRNA ligase inhibitor
How its trials ended
1,292 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 368 whose ending is known, 40% met their primary endpoint, 7% missed it and 53% stopped early.
- Completed, result not reported43334%
- Ongoing32425%
- Status unknown16713%
- Met its primary endpoint14912%
- Stopped: other or unclear836%
- Stopped: enrollment or feasibility514%
- Stopped: sponsor or business decision282%
- Stopped: lack of efficacy262%
- Missed its primary endpoint242%
- Stopped: funding40%
- Stopped: safety30%
Trials authorized in Canada
The 10 newest of 161; search them all in Canada trials| Oct 1, 2026 | A randomized trial of RIPK2 inhibitor OD-001 in combination with vedolizumab for moderately to severely active ulcerative colitisOD-001 (OD-07656) / Vedolizumab | Odyssey Therapeutics | Pending |
| Sep 17, 2026 | A phase 2, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy, safety, pharmacokinetics, and…PALI-2108 | Palisade Bio, Inc. | Pending |
| Aug 25, 2026 | A phase 2 platform basket study evaluating advanced therapies in subjects with moderately to severely active Crohn's disease or ulcerative colitisRisankizumab (ABBV-066) / Trosunilimab / ABBV-701 | AbbVie | Ongoing |
| Aug 12, 2026 | A phase III, multicenter, double-blind, placebo-controlled study to assess the efficacy and safety of induction therapy with RO7790121 in patients with…RO7790121 (TL1A (RVT-3101)) | Roche | Pending |
| May 20, 2026 | A phase 3 randomized, double-blind, and active-controlled, multicenter study to evaluate the efficacy and safety of JNJ-78934804 in participants with…JNJ-78934804 (guselkumab-golimumab) / Guselkumab | Johnson & Johnson | Ongoing |
| Apr 24, 2026 | A phase 2a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-8690 in adult participants with moderately to severely…MK-8690 | Merck & Co. (MSD) | Ongoing |
| Apr 2, 2026 | Master protocol title: a master protocol for phase 2, randomized, controlled studies of multiple interventions for the treatment of adults with moderately to…Mirikizumab (LY3074828) / LY4395089 | Eli Lilly | Ongoing |
| Mar 25, 2026 | A randomized, multicenter, double-blind, placebo-controlled development program to evaluate the efficacy and safety of LY4268989 (MORF-057) for the treatment…LY4268989 (MORF-057) | Eli Lilly | Ongoing |
| Feb 20, 2026 | A phase 2, multicenter, randomized, double-blind, active-controlled study of LY4268989 (MORF-057) co-administered with mirikizumab in adults with moderately to…LY4268989 (MORF-057) / Mirikizumab (LY3074828) | Eli Lilly | Ongoing |
| Feb 4, 2026 | A multi-centre, randomised controlled trial comparing fecal microbiota transplantation to placebo in an expanded ulcerative colitis population: a feasibility…Fecal microbiota for transplantation (FMT) | The Governors of The University of Alberta | Pending |
FDA orphan designations
Approved first, then open designations, newest first; 15 of 23| Aug 28, 2026 | StelaraTreatment of adults and pediatric patients 2 years of age and older with moderately to severely active ulcerative colitis | Janssen Biotech, Inc. | Approved |
| Oct 7, 2025 | SimponiTreatment of adults and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis | Janssen Biotech, Inc. | Approved |
| Feb 24, 2021 | HumiraTreatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The… | AbbVie, Inc. | Approved |
| Jun 26, 2020 | LialdaLialda (mesalamine) is indicated for the treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at… | Takeda Development Center Americas, Inc. | Approved |
| Sep 23, 2011 | RemicadeFor reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with… | Janssen Biotech, Inc. | Approved |
| Dec 20, 2006 | ColazalTreatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal… | Salix Pharmaceuticals, Inc. | Approved |
| Aug 9, 2021 | Mixture of delta 9-tetrahydrocannabinol glycosidesTreatment of pediatric ulcerative colitis between the ages of 0-18 years | Vitality Biopharma, Inc. | Designated |
| Mar 30, 2020 | Magnesium lysinate bis Resolvin E1Treatment of pediatric ulcerative colitis | Thetis Pharmaceuticals | Designated |
| Dec 30, 2019 | UpadacitinibTreatment of pediatric ulcerative colitis | AbbVie | Designated |
| Jan 17, 2018 | ApremilastTreatment of pediatric patients with ulcerative colitis | Amgen Inc. | Designated |
| Nov 16, 2017 | Cholera toxin B subunitTreatment of ulcerative colitis in pediatric patients | Aliment Wellness LLC | Designated |
| Aug 31, 2017 | 5-(4-carboxymethyl-phenylazo)-2-hydroxybenzoic acid…Treatment of pediatric ulcerative colitis (UC) | 9 Meters Biopharma, Inc. | Designated |
| Jun 27, 2017 | Hydrocortisone acetateTreatment of pediatric ulcerative colitis | Cristcot HCA, LLC | Designated |
| Jun 15, 2017 | Humanized immunoglobulin G4-variant monoclonal antibody…Treatment of ulcerative colitis in pediatric patients | Eli Lilly & Company | Designated |
| Dec 29, 2015 | OzanimodTreatment of pediatric (0 through 16 years of age) ulcerative colitis | Celgene Corporation | Designated |
Medicines authorised in the EU
Newest first| Feb 16, 2024 | VelsipityEtrasimod | Pfizer Europe MA EEIG | EMA ↗ |
| May 26, 2023 | OmvohMirikizumab | Eli Lilly Nederland B.V. | EMA ↗ |
| May 20, 2020 | ZeposiaOzanimod | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| May 18, 2018 | ZesslyInfliximab · biosimilar | Sandoz GmbH | EMA ↗ |
| May 22, 2014 | EntyvioVedolizumab | Takeda Pharma A/S | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA